Back to Search Start Over

Studies from Kyorin University in the Area of Glioblastomas Described [Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study]

Source :
Immunotherapy Weekly. December 14, 2022, 1481
Publication Year :
2022

Abstract

2022 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on glioblastomas are discussed in a new report. According to news originating from [...]

Details

Language :
English
ISSN :
10908625
Database :
Gale General OneFile
Journal :
Immunotherapy Weekly
Publication Type :
News
Accession number :
edsgcl.729665199